Published 11 October 2019 Lund researchers Anna Sundlöv and Katarina Sjögreen-Gleisner have developed a method to personalise treatment using a newly approved radioactive cancer drug – by taking images of the drug’s dispersion inside the patient. Their article won the best publication of the year prize awarded by the journal EJNMMI Physics. 177Lutetium-DOTATATE one day after injection (coloured ar

https://www.lucc.lu.se/article/researchers-lund-receive-prize-publication-year - 2025-07-05

Published 12 December 2019 Triple negative breast cancer is an aggressive type of cancer representing approximately nine percent of all breast cancer cases in Sweden. It is more common among younger women, has a high heredity factor and causes more frequent relapses earlier in the course of the disease than other breast cancers. Researchers have applied full genome sequencing to carry out detailed

https://www.lucc.lu.se/article/patient-specific-diagnostics-breast-cancers-are-difficult-cure - 2025-07-05

Published 12 December 2019 Chronic myeloid leukaemia (CML) is a slowly progressing form of blood cancer that attacks the blood-forming cells in the bone marrow. The condition requires lifelong treatment that can cause severe side effects. Rebecca Warfvinge maps stem cells in patients in the hope of identifying predictive markers for how the patient will react to therapy. She has now received an aw

https://www.lucc.lu.se/article/tailored-therapy-chronic-myeloid-leukaemia - 2025-07-05

Published 7 January 2020 The European Research Council today announced the winners of its latest Consolidator Grant competition: 301 top scientists and scholars across Europe. Funding for these researchers, part of the Horizon 2020 research and innovation programme, is worth in total EUR 600 million. Filipe Pereira at Lund University in Sweden is one of the 89 selected researchers, and will be awa

https://www.lucc.lu.se/article/prestigious-erc-grant-innovative-immunotherapy-research - 2025-07-05

Published 3 February 2020 Cancer patients responded better to immunotherapy and had a better prognosis if their melanoma tumours contained specific clusters of B cells, according to new research from Lund University in Sweden. The study is published in Nature. B cells linked to effective cancer immunotherapyCancer patients responded better to immunotherapy and had a better prognosis if their melan

https://www.lucc.lu.se/article/b-cells-linked-effective-cancer-immunotherapy - 2025-07-05

Published 3 February 2020 In a major study of hereditary breast cancer, a global network of researchers (including some from Lund University) has identified over 350 faults in DNA that increase an individual’s risk of developing the disease. The researchers believe that these faults can affect as many as 190 genes. Published in Nature Genetics, a scientific journal, the results are said to be the

https://www.lucc.lu.se/article/major-study-gives-most-comprehensive-map-breast-cancer-risk - 2025-07-05

Published 3 February 2020 In their quest to find new and better methods to make cancer cells more susceptible to treatment, Karin Lindkvist and her research group at Lund University in Sweden are looking into the world of molecules, using the X-rays at the MAX IV laboratory. The researchers believe that limiting the cells' access to sugar will make cancer cells more sensitive to treatment. Karin L

https://www.lucc.lu.se/article/researchers-believe-sugar-and-obesity-can-make-cancer-cells-more-difficult-kill - 2025-07-05

Published 20 April 2020 In recent years, RNA molecules, with the ability to affect or turn off pathogenic genes, have become promising drug candidates in several areas. However, it has been a challenge to develop techniques to deliver the RNA molecules into the cells where they have an effect. Researchers at Lund University in Sweden have now developed a sensitive technique that makes it possible

https://www.lucc.lu.se/article/rna-drugs-one-step-closer-be-being-used-cancer-treatment - 2025-07-05

Published 29 June 2020 By preventing sugar uptake, researchers succeeded in increasing the cancer cells’ sensitivity to chemotherapeutic treatment. The studies, led by researchers at Lund University in Sweden, were carried out on cancer cells in a lab environment. The results were recently published in the research journal Haematologica. Just like the body’s cells, cancer cells need energy like th

https://www.lucc.lu.se/article/starved-cancer-cells-became-more-sensitive-chemotherapy - 2025-07-05

Published 12 October 2020 A new way of identifying cancer biomarkers has been developed by researchers at Lund University in Sweden. The new technology allows very sensitive, quick and cost-effective identification of cancer biomarkers. The research is published in Nature Communications Biology. Carl Borrebaeck (Photo: apelöga) Today, every third person will get cancer in their lifetime, and the c

https://www.lucc.lu.se/article/novel-biomarker-technology-cancer-diagnostics - 2025-07-05

Published 12 October 2020 A new and promising approach for treatment of lung cancer has been developed by researchers at Lund University. The treatment combines a novel surgical approach with smart nanoparticles to specifically target lung tumors. The new study has been published in the July issue of Advanced Therapeutics. Illustration of the pH-responsive mesoporous silica nanoparticles designed

https://www.lucc.lu.se/article/new-promising-treatment-uses-smart-nanoparticles-target-lung-cancer - 2025-07-05

Published 12 October 2020 A new study from Lund University and Region Skåne in Sweden indicates that potency-enhancing PDE5 inhibitor drugs have an anti-cancer potential with the ability to improve the prognosis in patients with colorectal cancer. PDE5 inhibitors include a few approved drugs in which sildenafil (Viagra) is the most well-known. The article is published in Nature Communications. Wuq

https://www.lucc.lu.se/article/potency-enhancing-drugs-linked-decreased-risks-men-colorectal-cancer - 2025-07-05

Published 12 October 2020 Emma Hammarlund was one of six researchers from Lund University in Sweden that was granted five-year starting grants from the European Research Council. Emma Hammarlund Emma Hammarlund, geobiologist and researcher at the Division of Translational Cancer Research, will investigate how life could develop on our planet. The availability of oxygen has long been the prime focu

https://www.lucc.lu.se/article/lucc-researcher-receive-erc-starting-grant - 2025-07-05

Published 13 November 2020 Researchers at Lund University in Sweden have developed a computational model which is effective in detecting and identifying genetic mutations in breast tumours. The study, the largest of its kind in the world, includes results from over 3 200 patients with breast cancer. Lao Saal (Photo Olle Dahlbäck) The researchers used RNA sequencing, a sensitive, precise tool which

https://www.lucc.lu.se/article/new-analytical-model-detects-mutations-breast-cancer - 2025-07-05

Published 13 November 2020 A drug has shown great promise in the treatment of neuroblastoma, an aggressive form of childhood cancer. The study was led by researchers at Lund University in Sweden, and is published in the journal Science Translational Medicine. Karin Hansson and Daniel Bexell (Photo Åsa Hansdotter) Every year, about 800 children in the US are diagnosed with neuroblastoma, an aggress

https://www.lucc.lu.se/article/promising-treatment-aggressive-childhood-cancer - 2025-07-05

By kajsa_m [dot] paulsson [at] med [dot] lu [dot] se (Kajsa Paulsson) - published 18 December 2019 Markel has worked in the field of botulinum neurotoxins (BoNTs) during his PhD in Pål Stenmark's team, using X-ray crystallography and cryo-EM to solve the structure of several proteins related to the botulinum neurotoxins. His main cryo-EM project consisted in structural work on the 300 kDa complex

https://www.microscopy.lu.se/article/markel-martinez - 2025-07-05

Published 18 December 2019 I work as a researcher at the Faculty of Medicine studying protein-protein complexes arising at the host-pathogen interface, with the aim of understanding how pathogens evade the human immune defence. The main methods we are using are quantitative and structural mass spectrometry (cross-linking and hydrogen-deuterium exchange) in combination with single-particle cryo-EM.

https://www.microscopy.lu.se/article/lotta-happonen-short-biography - 2025-07-05

Published 18 December 2019 Derek Logan's research group is based at the Dept. of Biochemistry and Structural Biology at Lund University. His research focuses on the elucidation of structure-function relationships in proteins and their complexes. A particular focus is on allosteric regulation of the essential enzyme ribonucleotide reductase and drug design against the medically important galectin f

https://www.microscopy.lu.se/article/derek-logan-short-biography - 2025-07-05

Published 18 December 2019 Prof. Stenmark leads a research team at EMV, Lund university. He focuses on structure-based drug design, both in the development of small molecule drugs targeting cancer and in the engineering of protein drugs (e.g. neurotoxins). The main methods used are X-ray crystallography and single particle cryo-EM.

https://www.microscopy.lu.se/article/pal-stenmark-short-biography - 2025-07-05

Published 18 December 2019 Prof. Wallenberg is leading a group in solid state chemistry/nanoscience engineering at the Chemistry Institution, LU, with characterisation of structure and chemical composition of materials down to the atomic level as a special topic.  Materials range from inorganic compunds to  semiconductors to biological structures. He is the director of nCHREM, the national center

https://www.microscopy.lu.se/article/reine-wallenberg-short-biography - 2025-07-05